Divi's Lab.
Divi's Lab. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
The company targets **double-digit growth** in revenue and sales consistently, as stated by both Dr. Divi’s Laboratories aims for consistent double-digit revenue growth driven by a healthy product mix and diversified customer base.
From Divi's Lab.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company targets **double-digit growth** in revenue and sales consistently, as stated by both Dr. Kiran S. Divi and Nilima Prasad Divi.
- Growth is driven by ongoing **validation and commercialization of new projects**, including peptides and small molecules.
- Several validation batches are continuing, with multiple projects in different development stages expected to contribute revenue gradually.
- The launch of **commercial volumes post-regulatory approvals** will positively impact growth, though timelines depend on approvals.
- Expansion projects (capex of around ₹2,000 crores, 70% incurred) will support capacity additions and future growth.
- Growth assumes a **healthy product mix** without over-reliance on any single product or customer.
- Macro factors like crude oil prices and geopolitical situations in the Middle East can influence input costs and inventory levels but underlying demand remains strong.
- The company aims to be a **largest integrated player globally in peptides**, expanding capacities accordingly.
Profitability & Margins
See what Divi's Lab. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Divi’s Laboratories has three major ongoing capex projects nearing completion, with about 70% of the ₹2,000 crores investment capitalized so far (Page 13).
- These projects include capacity expansions supporting validation batches and future commercial production, with one related long-term contract negotiation in the contrast media segment (Page 9, 13, 14).
- Significant capacity expansions are underway in peptide manufacturing, including installing multiple 3,000-liter solid-phase peptide synthesis (SPPS) lines to capture future opportunities (Page 13).
- Unit 3 plays a strategic role by supporting backward integration, pre-chemistry operations, and enabling efficient capacity utilization through phased manufacturing transfers (Page 5, 14).
- Investments continue in technology development such as continuous flow chemistry, biocatalysis, advanced automation, green chemistry, energy efficiency, and process intensification to improve safety and productivity (Page 5, 14).
- Capital work in progress stands at ₹2,034 crores as of June 30, 2026 (Page 6).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divi's Lab. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Divi's Laboratories is currently engaged in validation batches for several projects, including three major dedicated capex projects involving different products.
- Due to confidentiality and CDAs, specific details on order book size, product names, or quantities cannot be disclosed.
- The company has supplied validation quantities for about 4 new DMFs as part of their generic portfolio, which are undergoing customer qualification.
- Several projects are in various pipeline stages: clinical studies, pre-validation, and validations.
- Commercial supplies will only start after customer qualifications and regulatory approvals.
- The firm expects a double-digit growth in revenue, supported by ongoing and upcoming validations leading to commercial orders.
- Negotiations are ongoing with some customers for long-term contracts, particularly in the iodine-based contrast media segment.
- Overall, the order book and projects pipeline are robust but exact figures are not publicly shared due to contractual obligations.
Divi's Lab. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divis Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Divi's Lab. Q1 FY27 results?
The company targets **double-digit growth** in revenue and sales consistently, as stated by both Dr. Divi’s Laboratories aims for consistent double-digit revenue growth driven by a healthy product mix and diversified customer base.
What is Divi's Lab. share price analysis?
Divi's Lab. currently shows a below-average growth signal. The stock trades at a P/E of 76.6 with a market cap of ₹228,223 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divi's Lab. planning capital expenditure?
Divi’s Laboratories has three major ongoing capex projects nearing completion, with about 70% of the ₹2,000 crores investment capitalized so far (Page 13).
Keep Divi's Lab. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.